心脏遗传性离子通道病的非药物治疗进展

Advances of Non-pharmaceutical Therapy on Cardiac Heredity Ion Channelopathy

遗传性离子通道病多以猝死或心脏骤停为首发临床表现。除常规的抗心律失常药物之外,心律转复除颤器植入已被纳入高风险心脏遗传性离子通道病的重要治疗。近年来有研究显示通过对这些患者诱发触发灶进而消融病灶的局部基质可以达到治疗目的,然而恰当的诱发策略、消融术式的选择等仍需深入研究。目前,左侧星状神经节切除术也被证明可用于部分患者的治疗,干细胞移植和基因治疗也成为了治疗的新方向。遗传性离子通道病的非药物治疗目前已取得很大的进展,但未来尚有许多亟待解决的问题。

Most patients usually with cardiac heredity ion channelopathy have sudden death or cardiac arrest as the initial clinical manifestation.In addition to conventional antiarrhythmic drugs,cardio arrhythmia defibrillator implants have been incorporated as an important treatment for high risk individuals with cardiac heredity ion channelopathy. In recent years,a few studies have shown that inducing the unstable triggering foci so as to ablate the abnormal substrate of the patients can achieve treatment purposes.However,this is required to have further study to understand how to choose an appropriate induced strategy and an ablation method.At present,the effectiveness of left stellate ganglion resection for the treatment of partial cardiac heredity ion channelopathy has been demonstrated. Stem cell transplantation and gene therapy are also proposed as a new idea for the treatment of patients with cardiac heredity ion channelopathy.So far there has been a great deal of progress in the non-pharmaceutical therapy of cardiac heredity ion channelopathy,while there are still many problems requiring solutions in the future.